Access cutting-edge solid tumors harboring met amplification treatment through this clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Grand Rapids location
Preparing your pre-screening questions…
Access solid tumors harboring met amplification specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related solid tumors harboring met amplification treatment provided free
Check if you qualify for this solid tumors harboring met amplification clinical trial in Grand Rapids, MI
No-Cost Study Care
Local to Grand Rapids
Convenient for MI residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Sponsor: AbbVie
Yes, this clinical trial (NCT07196644) has an active research site in Grand Rapids, MI that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for solid tumors harboring met amplification treatment options in Grand Rapids, MI, this clinical trial (NCT07196644) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Grand Rapids research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors harboring met amplification specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all solid tumors harboring met amplification clinical trials near you to find additional studies recruiting in your area.
See all advanced solid tumors clinical trials recruiting in Grand Rapids — not just this study.
Browse Advanced Solid Tumors Trials in Grand Rapids →